Douglas Netz, MD
Interventional Cardiology · Lincoln, NENPI 1356436638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novartis at 27.2% of the total. That places this record below the midpoint for interventional cardiology clinicians in NE, where the typical reported total is $6,648.
Across 187 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$867
- Boston Scientific$616
- Pfizer$318
- Amgen$260
- E.r. Squibb & Sons, L.L.C.$214
- Merck$126
- plus $785 from 23 others
Across 8 payments — averaging $2530.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$20K
What the payments were for
- Food & beverage$3,186100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 62 | $867 |
| Boston Scientific | 13 | $616 |
| Pfizer | 24 | $318 |
| Amgen | 14 | $260 |
| E.r. Squibb & Sons, L.L.C. | 19 | $214 |
| Merck | 9 | $126 |
| Itamar Medical Inc | 1 | $87 |
| Boehringer Ingelheim | 5 | $83 |
| Johnson & Johnson | 5 | $69 |
| Impulse Dynamics (USA) Inc. | 3 | $63 |
| Novo Nordisk | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Heartflow, Inc. | 3 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $36 |
| Philips North America LLC | 1 | $29 |
| Medtronic(2 entities) | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Bridgebio Pharma, Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $26 |
| Gilead | 2 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Abbott | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $12 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,186 in reported general payments places this provider in the 30th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 210 | $194,970 |
| EliquisApixaban | 201 | $176,010 |
| EntrestoSacubitril/Valsartan | 95 | $88,808 |
| JardianceEmpagliflozin | 93 | $79,809 |
| Repatha SureclickEvolocumab | 98 | $61,023 |
| MultaqDronedarone Hcl | 25 | $20,945 |
| Praluent PenAlirocumab | 31 | $17,044 |
| Flecainide Acetate | 245 | $9,491 |
| Ranolazine ErRanolazine | 115 | $8,399 |
| Midodrine Hcl | 129 | $7,641 |
| Metoprolol Succinate | 516 | $6,488 |
| Potassium Chloride | 240 | $4,966 |
| BrilintaTicagrelor | 11 | $4,643 |
| Atorvastatin Calcium | 443 | $4,347 |
| SotalolSotalol Hcl | 198 | $3,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $69 | $194,970210 claims |
| PfizerEliquis | $318 | $176,010201 claims |
| NovartisEntresto | $867 | $88,80895 claims |
| Boehringer IngelheimJardiance | $83 | $79,80993 claims |
| Sanofi-aventis U.S. LLCMultaq | $46 | $20,94525 claims |
| AstraZenecaBrilinta | $13 | $4,64311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Lincoln
- Brock CookmanLincoln$782K
- Matthew JohnsonLincoln$162K
- Steven MartinLincoln$55K
- Natraj KattaLincoln$18K
- Hemantha KoduriLincoln$10K
- Denes KorpasLincoln$9K
- Harpaul BajwaLincoln$7K
- Zachary SingsankLincoln$4K
- Vishwajeth BhoopalamLincoln$3K
- Melissa AlvarezLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.